GUANGZHOU, China, Jan. 16, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced significant progress in its strategic collaboration with leading domestic pharmaceutical companies to accelerate the growth of its internet hospital business. The Company expects these partnerships to become a core component of its long-term strategy to expand online hospital operations and enhance overall profitability. Against the backdrop of China's accelerating population aging and evolving demographic structure, the domestic internet hospital and online pharmaceutical sales market has exp

GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025. Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through

GUANGZHOU, China, Oct. 10, 2025 /PRNewswire/ -- POMDOCTOR LIMITED (NASDAQ:POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the underwriter of its initial public offering (the "Offering") has exercised in full its option to purchase an additional 750,000 American Depositary Shares ("ADSs") at a public offering price of $4.00 per ADS to cover over-allotments. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. Gross proceeds to the Company from the offering, including funds received from the prior closing and exercise of this over-allotment option, totaled $23,000,016, before